Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687542 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT02687542: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT02687542 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 108 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02687542, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Primary Outcome
A paper Hauser diary was utilized to record motor state for half-hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.
Interventions
- DRUG Placebo
- DRUG PF-06649751 low dose (1 mg QD)
- DRUG PF-06649751 middle dose 1 (3 mg QD)
- DRUG PF-06649751 middle dose 2 (7 mg QD)
- DRUG PF-06649751 high dose (15 mg QD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2016-03-03 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 2 |
Why NCT02687542 stopped before completion
NCT02687542 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02687542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02687542 about?
NCT02687542 is a clinical study titled "Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations". The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
What is the current status of trial NCT02687542?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2016-03-03. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT02687542?
The interventions under investigation include: Placebo (DRUG), PF-06649751 low dose (1 mg QD) (DRUG), PF-06649751 middle dose 1 (3 mg QD) (DRUG), PF-06649751 middle dose 2 (7 mg QD) (DRUG), PF-06649751 high dose (15 mg QD) (DRUG).
Who is sponsoring clinical trial NCT02687542?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02687542's enrollment target sits among peer trials
108 640th of 2000 higher than 1,355 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI